Bellerophon, Osiris Therapeutics, Biospecifics Technologies, Aevi Genomic Medicine and Curis were last week’s top gainers on the NASDAQ Biotechnology Index.
Over the last trading week, the NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) decreased slightly by 1 percent to 3,704.4 points as of 12:00 p.m. EST on Friday (September 14).
Last week was filled with exciting milestones and company news investors have showed excitement over. On Wednesday (September 12), Nemaura Medical (NASDAQ:NMRD) announced positive interim data for its continuous glucose monitor, the SugarBEAT.
This news means the company expects to finish the US study and submit applications for approval to the US Food and Drug Administration (FDA) in Q1 2019.
Against that backdrop, a number of other NASDAQ biotech stocks saw significant share price increases last week. The five top gainers are as follows:
- Bellerophon Therapeutics (NASDAQ:BLPH)
- Osiris Therapeutics (NASDAQ:OSIR)
- Biospecifics Technologies (NASDAQ:BSTC)
- Aevi Genomic Medicine (NASDAQ:GNMX)
- Curis (NASDAQ:CRIS)
Here’s a closer look at those companies and what moved their share prices last week. Share prices are quoted in US dollars and were taken from Google Finance as of 12:00 p.m. EST on Friday.
Bellerophon is first on our top weekly NASDAQ biotech stocks with a share price increase of 46.74 percent over last week’s trading period to reach $1.25.
While the company didn’t have any news last week, it did present at the Rodman & Renshaw Annual Global Investment Conference on September 5, which may have carried its share price movement.
The company specializes in biotherapeutics and is developing products to treat cardiopulmonary and cardiac diseases. In its pipeline are three product candidates featuring the company’s INOpulse technology. One is a treatment for pulmonary arterial hypertension, and the other two are for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease and pulmonary hypertension associated with interstitial lung disease.
Osiris is developing regenerative medicine products to improve patient healthcare outcomes and costs. The company is known for its Grafix line of products in orthopedics, sports medicine and wound care. Over the past trading week Osiris’ share price increased 35.85 percent to $11.54.
Although the company didn’t have any news in the previous week it did have a big announcement in early August that the company would re-list on the NASDAQ global market. In late August, Osiris announced a peer-reviewed publication which had positive results for its Grafix patients treating chronic diabetic foot ulcers.
Middle of the pack on our weekly NASDAQ biotech stocks list is Biospecifics Tech, which is developing collagenase-based therapies. The company’s collagenase-based product Xiaflex is marketed in the US and in Europe under the name Xiapex.
Similar to other companies on the list this week, Biospecifics didn’t have any news in the past week, however it present at two conferences on September 6 and 7. One was an investor specific conference, whereas the other was a biotech industry conference. Biospecifics share price increased 21.05 percent to $60.11.
Aevi Genomic Medicine
Aevi didn’t have any news in last week’s trading period, although it most recently presented at the H.C. Wainwright Global Investment Conference in early September. Over the five-day trading period, shares of the company increased 12.16 percent to $1.28.
The company’s focus is on working with genomic medicine to translate genetic discoveries into novel therapies, such as with AEVI-001. Aside from this trial, the company is also working on treatments for Crohn’s disease and another undisclosed rare pediatric disease.
With a 8.84 percent share price increase to $1.60, Curis lands last on our weekly top NASDAQ biotech stocks.
Like other companies on our list, the company’s most recent news was it presenting at a conference in early September. Curis presented at the Baird 2018 Global Healthcare Conference.
Curis is a biotech developing treatments for cancers, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors. The company receives royalty income from the approved product, Erivedge, which was developed and marketed to Genentech.
Don’t forget to follow us at @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Biotech Stocks articles is retrieved each Friday at 1:00 p.m. EST using Globe and Mail’s Stock Filter. Only companies with a market capitalization greater than $50 million and lower than $500 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Gabrielle Lakusta, hold no direct investment interest in any company mentioned in this article.